新型心肌球蛋白抑制剂治疗肥厚型心肌病。
Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy.
机构信息
Department of Molecular and Cellular Pharmacology, University of Miami, Miller School of Medicine, Miami, FL, USA.
出版信息
J Gen Physiol. 2024 Oct 7;156(10). doi: 10.1085/jgp.202413640. Epub 2024 Aug 12.
Abstract
New RLC-1 small-molecule inhibits actomyosin interactions, reduces contractile force, and speeds up myosin cross-bridge kinetics.
摘要
新型 RLC-1 小分子抑制肌动球蛋白相互作用，降低收缩力，并加快肌球蛋白横桥动力学。
相似文献
1
Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy.
J Gen Physiol. 2024 Oct 7;156(10). doi: 10.1085/jgp.202413640. Epub 2024 Aug 12.
2
Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy.
Med. 2024 Jul 12;5(7):655-659. doi: 10.1016/j.medj.2024.06.001.
3
The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy.
Can J Cardiol. 2024 May;40(5):800-819. doi: 10.1016/j.cjca.2024.01.022. Epub 2024 Jan 26.
4
Target population for a selective cardiac myosin inhibitor in hypertrophic obstructive cardiomyopathy: Real-life estimation from the French register of hypertrophic cardiomyopathy (REMY).
Arch Cardiovasc Dis. 2024 Jun-Jul;117(6-7):427-432. doi: 10.1016/j.acvd.2024.04.001. Epub 2024 May 7.
5
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials.
Open Heart. 2025 Feb 23;12(1):e003215. doi: 10.1136/openhrt-2025-003215.
6
Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review.
Am J Cardiovasc Drugs. 2024 Sep;24(5):591-602. doi: 10.1007/s40256-024-00667-z. Epub 2024 Jul 19.
7
First-in-class cardiac myosin inhibitor reduces symptoms of HCM.
Nat Rev Cardiol. 2020 Nov;17(11):677. doi: 10.1038/s41569-020-00453-9.
8
Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management.
Ann Pharmacother. 2024 Mar;58(3):273-285. doi: 10.1177/10600280231180000. Epub 2023 Jun 16.
9
Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies.
Annu Rev Genomics Hum Genet. 2019 Aug 31;20:129-153. doi: 10.1146/annurev-genom-083118-015306. Epub 2019 Apr 12.
10
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
本文引用的文献
1
Mechanisms of a novel regulatory light chain-dependent cardiac myosin inhibitor.
J Gen Physiol. 2024 Oct 7;156(10). doi: 10.1085/jgp.202313503. Epub 2024 Jul 31.
2
Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review.
Am J Cardiovasc Drugs. 2024 Sep;24(5):591-602. doi: 10.1007/s40256-024-00667-z. Epub 2024 Jul 19.
3
Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction.
Nat Commun. 2024 Jun 7;15(1):4885. doi: 10.1038/s41467-024-47587-9.
4
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.
JACC Heart Fail. 2024 Jan;12(1):199-215. doi: 10.1016/j.jchf.2023.10.004. Epub 2023 Nov 29.
5
Cryo-EM structure of the human cardiac myosin filament.
Nature. 2023 Nov;623(7988):853-862. doi: 10.1038/s41586-023-06691-4. Epub 2023 Nov 1.
6
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy.
Sci Rep. 2022 Dec 28;12(1):22501. doi: 10.1038/s41598-022-26889-2.
7
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.
J Med Chem. 2021 Oct 14;64(19):14142-14152. doi: 10.1021/acs.jmedchem.1c01290. Epub 2021 Oct 4.
8
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
9
Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy.
Int J Cardiol. 2020 Nov 1;318:94-100. doi: 10.1016/j.ijcard.2020.07.036. Epub 2020 Jul 29.
10
Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Circ Heart Fail. 2020 Jun;13(6):e006853. doi: 10.1161/CIRCHEARTFAILURE.120.006853. Epub 2020 Jun 5.
Zotero 插件